Gyre Therapeutics, Inc. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8a15d60e-293b-47a4-89c0-7a91d6ede62a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $9.9M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-106251 |
| FY 2024 | $17.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-040279 |
| FY 2023 | $-85.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-037242 |
| FY 2022 | $4.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-037242 |
| FY 2021 | $-87.9M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-012877 |
| FY 2020 | $-56.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-010823 |
| FY 2019 | $-55.2M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-005546 |
| FY 2018 | $-30.1M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006879 |
| FY 2017 | $-21.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-006216 |
| FY 2016 | $-16.9M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003722 |
| FY 2015 | $-14.8M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-498295 |
| FY 2014 | $-6.6M | 2014-01-01 – 2014-12-31 | evidence 0001193125-16-498295 |
| FY 2013 | $-10.0M | 2013-01-01 – 2013-12-31 | evidence 0001193125-16-498295 |
| FY 2012 | $-7.0M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-109464 |
| FY 2011 | $-8.5M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-099259 |
| FY 2010 | $10.9M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-099259 |
| FY 2009 | $-39.4M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-099259 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Gyre Therapeutics, Inc. — all facts · Revenue · Operating Income